奧馬珠單抗治療阿司匹林哮喘合并中耳炎和鼻竇炎一例
打開文本圖片集
摘要：奧馬珠單抗是一種重組人源化單克隆抗體，為抗IgE靶向生物制劑，是全球首個獲批治療中至重度支氣管哮喘的靶向治療藥物。本文對1例阿司匹林哮喘伴分泌性中耳炎及鼻竇炎患者進行回顧性分析，探討奧馬珠單抗在治療哮喘及其合并癥中的價值，為臨床實踐提供依據(jù)。
關(guān)鍵詞：奧馬珠單抗；哮喘；鼻竇炎；中耳炎
中圖分類號： R593.1 文獻標(biāo)志碼： B 文章編號：1000-503X（2023）04-0699-04
DOI：10.3881/j.issn.1000-503X.15265
Omalizumab Treats Aspirin-Induced Asthma Complicated With
Nasosinusitis and Otitis Media：Report of One Case
TANG Rui1，LEI Shubin2，WANG Yi3
1Department of Allergy，Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease，
National Clinical Research Center for Dermatologic and Immunologic Diseases，
PUMC Hospital，CAMS and PUMC，Beijing 100730，China
2Eight-Year Program of Clinical Medicine，CAMS and PUMC，Beijing 100730，China
3Department of Otolaryngology and Head and Neck Surgery，PUMC Hospital，CAMS and PUMC，Beijing 100730，China
Corresponding author：WANG Yi Tel：010-69151601，E-mail：ywin6727@yahoo.com
ABSTRACT：Omalizumab，as a biological agent targeting IgE，is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media，we discussed the value of omalizumab in the treatment of asthma and its complications，aiming to provide a reference for clinical practice.
Key words：omalizumab；asthma；nasosinusitis；otitis media
Acta Acad Med Sin，2023，45（4）：699-702
奧馬珠單抗是一種重組人源化單克隆抗體，為抗IgE靶向生物制劑，是全球首個獲批治療中至重度支氣管哮喘的靶向治療藥物，目前已證實奧馬珠單抗可有效緩解哮喘發(fā)作期癥狀、減低哮喘發(fā)作頻率、提高患者生活質(zhì)量［1-2］。（剩余4631字）